Table 5.

Effect of maintaining Child-Pugh scores on patients’ outcomes in each subgroup 4 weeks after treatment commencement

	n	Median overall survival, months	Hazard ratio (95% CI)	p valuea
Age
<69 years	86	13.1	1.281 (0.785–2.091)	0.32
≥69 years	97	16.1	2.120 (1.336–3.365)	0.001
Gender
Female	34	12.0	1.646 (0.749–3.619)	0.21
Male	149	15.6	1.654 (1.142–2.396)	0.008
ECOG performance status
1–3	14	7.1	1.199 (0.363–3.955)	0.77
0	169	15.5	1.601 (1.125–2.278)	0.009
Hepatitis B virus surface antigen
Positive	51	12.2	1.265 (0.662–2.415)	0.48
Negative	132	16.2	1.832 (1.237–2.712)	0.003
Hepatitis C virus antibody
Negative	89	12.4	1.663 (1.025–2.699)	0.039
Positive	94	16.6	1.739 (1.090–2.773)	0.020
Child-Pugh score
6	92	13.0	1.407 (0.851–2.326)	0.18
5	91	15.6	1.996 (1.251–3.187)	0.004
Branched-chain amino acid intake
Positive	28	12.0	1.232 (0.546–2.778)	0.62
Negative	155	15.2	1.684 (1.163–2.440)	0.006
Vascular invasion
Positive	73	9.0	1.468 (0.888–2.429)	0.13
Negative	110	19.2	1.777 (1.134–2.784)	0.012
Extrahepatic lesion
Positive	44	7.7	1.256 (0.661–2.390)	0.49
Negative	139	17.2	1.624 (1.089–2.422)	0.017
AFP
≥400 ng/mL	67	10.5	2.069 (1.215–3.523)	0.0079
<400 ng/mL	116	18.6	1.439 (0.934–2.217)	0.099
Treatment procedure
Sorafenib	46	13.0	1.195 (0.620–2.301)	0.59
HAIC	137	15.6	1.709 (1.144–2.552)	0.009
Best response to treatment
Progressive disease or not evaluable	64	7.7	1.458 (0.869–2.445)	0.15
Complete response, partial response, or stable disease	119	22.0	1.667 (1.072–2.593)	0.023

AFP, α-fetoprotein; HAIC, hepatic arterial infusion chemotherapy; ECOG, Eastern Cooperative Oncology Group.

^aCox proportional hazards regression model.